NanoZolid® Technology Patent Portfolio Approved World Wide
March 29, 2021 02:45 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that LIDDS initial five patent families which protect drugs formulated with NanoZolid® technology are now approved in all countries concerned. In...
LIDDS enters R&D agreement with potential exclusive, global product license option
March 02, 2021 08:50 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that an agreement has been signed with Johnson & Johnson Enterprise Innovation Inc. to develop an oncology product based on the NanoZolid®...
LIDDS Interim report January – December 2020
February 25, 2021 02:45 ET
|
LIDDS AB
JANUARY – DECEMBER 2020 Net sales amounted to MSEK 0.3 (0.0)Operating expenses amounted to MSEK -33.0 (-31.4)Profit/loss before and after tax amounted to MSEK -32.3 (-31.4)Earnings per share amounted...
LIDDS and Pharmidea signs manufacturing agreement
February 25, 2021 02:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a collaboration agreement has been signed with the R&D and Production company PharmIdea SIA in Riga, Latvia. PharmIdea focuses on anti-cancer...
LIDDS files patent application for method to treat brain cancer with intratumoral depot injections
February 24, 2021 11:19 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a patent application related to NanoZolid® for treatment of brain cancers was filed to the European patent office. The patent application relates...
European Urology Focus has accepted a scientific article describing LIDDS Phase IIb study results with Liproca® Depot
February 04, 2021 04:00 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announces that a scientific article will be published in the highly ranked European Urology Focus describing LIDDS clinical Phase IIb study, LPC-004, and its clinical...
LIDDS has decided to apply for listing of the company’s shares on Nasdaq Stockholm Main Market in 2021
December 22, 2020 02:45 ET
|
LIDDS AB
STOCKHOLM – LIDDS (Nasdaq First North: LIDDS) announced today that the company will apply for a relisting of its shares from Nasdaq First North to Nasdaq Stockholm Main Market in 2021. LIDDS is...
Update on Chinese Conditional Market Approval (CMA) for Liproca® Depot
December 18, 2020 02:30 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) A newly revised guideline from the Chinese National Medical Products Administration (NMPA) has extended the requirements to a full registration dossier for the...
LIDDS AB (publ) announces the appointment of Nina Herne as CEO
December 15, 2020 14:15 ET
|
LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that Nina Herne will assume the role of Chief Executive Officer for LIDDS, effective April 19, 2021. Nina Herne has successfully held multiple senior...
LIDDS Interim report January – September 2020
November 19, 2020 02:45 ET
|
LIDDS AB
JANUARY – SEPTEMBER 2020 Net sales amounted to MSEK 0.0 (0.0)Operating expenses amounted to MSEK -19.8 (-22.9)Profit/loss before and after tax amounted to MSEK -19.8 (-22.9)Earnings per share...